EP1668023A1 - Nucleosides b-l et leur utilisation comme agents pharmaceutiques pour traiter des affections virales - Google Patents

Nucleosides b-l et leur utilisation comme agents pharmaceutiques pour traiter des affections virales

Info

Publication number
EP1668023A1
EP1668023A1 EP04786771A EP04786771A EP1668023A1 EP 1668023 A1 EP1668023 A1 EP 1668023A1 EP 04786771 A EP04786771 A EP 04786771A EP 04786771 A EP04786771 A EP 04786771A EP 1668023 A1 EP1668023 A1 EP 1668023A1
Authority
EP
European Patent Office
Prior art keywords
nucleoside
agents
nucleic acid
pharmaceutical agent
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04786771A
Other languages
German (de)
English (en)
Inventor
Eckart Matthes
Martin Janta-Lipinski
Hans Will
Hüseyin SIRMA
Lin Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of EP1668023A1 publication Critical patent/EP1668023A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/09—Pyrimidine radicals with arabinosyl as the saccharide radical

Definitions

  • ⁇ -L nucleosides and their use as pharmaceutical agents for the treatment of viral diseases
  • the invention relates to new ⁇ -L-5-methylcytosine nucleosides of the structure as can be seen from the following formulas I and II,
  • ⁇ -L-5-methylcytosine nucleosides, their acceptable salts, or their prodrugs can be used alone or in combination with other ⁇ -L-nucleosides, with 3-deazauridine or with other anti-HBV-active compounds. Areas of application of the invention are medicine and the pharmaceutical industry.
  • HBV hepatitis B
  • infectious disease the chronic course of which affects about 350 million people worldwide, especially in Southeast Asia, Africa and South America.
  • hepatitis B infections lead to fatal outcome from liver function failure.
  • the chronic course is associated with a greatly increased risk of a primary liver carcino, which in China alone leads to around one million new cases each year. While the exact mechanism by which HBV can induce liver tumors is unknown, it can be assumed that tumor induction is closely related to HBV-induced chronic inflammation, developing cirrhosis and regeneration processes in liver tissue.
  • the genetically engineered vaccine which has been available for many years, is not suitable for the treatment of hepatitis B because it does not help people who are already infected and cannot stop the chronic course mentioned.
  • genetically engineered ⁇ -interferon has proven particularly useful in the treatment of HBV infections. It is a cytokine with broad antiviral and immunomodulating activity. However, it is only effective in about 33% of patients, has significant side effects and cannot be given orally.
  • lamivudine (ß-L-2 ", 3" -dideoxy-3 " ⁇ thiacytidine), also known as thiacytidine (3TC), which is from Liotta et al., In US Patent 5 539 116.
  • Lamivudine belongs to a group of so-called ß-L nucleosides. They are mirror images of the naturally occurring ß-D nucleosides and were long considered to be non-enzymatic and therefore ineffective in biological systems.
  • L-nucleosides are not only effective inhibitors of HBV replication, but also of HIV replication. So z. B. Lamivudine also approved for the treatment of HIV infection. Further, already mentioned ß-L-cytosine nucleosides, such as L-ddC, L-5FddC, L-FddeC, FTC are also strong inhibitors of HIV replication, the importance of which for therapy lies in new effective compounds for combination therapy To have available and to be able to counter possible development of resistance (Menendez-Arias, Trends Pharmacol Sei 2002, 23: 381-388). There are also a number of ß-L nucleosides that only replicate HBV (e.g. L-FMAU, L-TdR, L-CdR, L-3 "FddC, L-ddeC), others that only Inhibit HIV replication (e.g. abacavir).
  • ⁇ -L-nucleosides are taken up by the HBV- or HIV-infected cells and have to be converted by the cell's own enzymes to the nucleoside triphosphates. Only in this form can they bind their actual target, the HBV-DNA polymerase, or the reverse transcriptase in competition to the normal substrates and exert a strong inhibition. As a result, the viral genomes can no longer be synthesized and virus production comes to a standstill. This inhibition must be selective, ie, it must remain restricted to the viral polymerases and must not include the cellular DNA polymerases, because otherwise the proliferation of rapidly proliferating cells would be impaired as a result of the inhibition of the synthesis of cellular DNA.
  • the invention is based on the object of developing new antivirally active ⁇ -L-methylcytosine nucleosides which are particularly effective against hepatitis B virus infections and HIV infections and which, with good tolerability and low toxicity, are highly effective against this infection.
  • R 2 H, OH
  • Phosphonate monophosphate
  • Mean diphosphate or triphosphate namely,
  • R 6 H
  • F and R 7 mean H
  • ß-L-5-methyldeoxycytidine (ß-L-MetCdR), ß-L-2 ", 3" -dideoxy-5-methylcytidine (ß-L-ddMetC), ß-L-2 ", 3 "-Didehydro-2", 3 "-dideoxy-5-methylcytidine (ß-L-ddeMetC), ß-L-arabinofuranosyl-5-methylcytosine (ß-L-AraMetC), ß-L-2", 3 "- Didehydro-2 ", 3” -dideoxy-2 "-fluoro-5-methylcytidine (ß-L-FddeMetC), ß-L- 2 "-fluoroarabinofuranosyl-5-methylcytosine (ß-L-FMAC) and ß-L-3" -azido-2 ", 3" -dideoxy-5-methylcytidine (LN 3 MetCdR),
  • 3-deazauridine activates cellular deoxycytidine kinase and its intracellularly formed triphosphate is also able to inhibit cellular CTP synthase (Gao et al., Nucleosides Nucleotides Nucleic Acids 2000, 19: 371-377). These two effects on the cellular deoxycytidine metabolism have the consequence that 3-deazauridine leads to higher triphosphate levels of the ⁇ -L-5-methyl-cytosine nucleosides according to the invention and their effectiveness against HBV replication is thereby greatly increased.
  • nucleosides according to the invention ie the ⁇ -L-methylcytosine nucleosides
  • the nucleosides or nucleoside analogs according to the invention are structures which differ in some features from the naturally occurring nucleosides, but there is an analogy to naturally occurring nucleosides in at least two essential points.
  • a - possibly also modified - nucleobase is always required, which is necessary as a binding site to the complementary viral DNA parent strand.
  • nucleoside triphosphate there must be a functional group in the former 5 "position which allows the formation of an energy-rich triphosphate from the nucleosides according to the invention or the nucleoside analogues.
  • the nucleoside triphosphate can only be inhibited in the
  • direct administration of the active nucleoside triphosphate as an active ingredient is less preferred, since these are broken down in the blood plasma by non-specific phosphatases to the corresponding free nucleoside analogues.
  • triphosphates due to their negative charge, triphosphates cannot cross a cell membrane and thus cannot reach the site of action within the cell.
  • viruses such as herpes viruses
  • Some viruses are able, with their own viral thymidine kinase, to metabolize the nucleoside analogues according to the invention in infected cells to the respective nucleoside monophosphate, which in turn changes from the cell's own enzyme to triphosphate, the actual active metabolite. is converted.
  • the triphosphate competes as an alternative substrate with the natural substrate for incorporation into the DNA.
  • the lack of a 3 "hydroxyl function or an analog group prevents further chain extension.
  • the triphosphate acts as a competitive inhibitor of the viral DNA polymerase. It is so in many ways possible that the replication of the
  • Virus is disrupted or completely prevented.
  • derivatives of the nucleosides according to the invention are used. These can be structures which have modifications which in particular increase the antiviral activity. However, it can also be a salt, a phosphonate, a monophosphate, a diphosphate, a triphosphate, an ester or a salt of such esters.
  • such compounds can be used effectively in antiviral prophylaxis and therapy and have little or no side effects.
  • the 5-methylcytosine- ⁇ -L-nucleosides according to the invention are ⁇ -L-5-methyldeoxycytidine, 5-methylcytosine, ⁇ -L- 2 ", 3" -dideoxy-5-methylcytidine ( L-ddMetC), ß-L-2 ", 3" - didehydro-2 ", 3” -dideoxy-5-methylcytidine (L-ddeMetC), ß-L-arabinofuranosyl-5-methylcytosine (L-MetaraC), ß -L-2 "-Fluoro-arabinofuranosyl-5-methylcytosine (L-FMAC), ß-L-2", 3 "-Dide- hydro-2", 3 "-dideoxy-2” -fluoro-5-methylcytidine ( L-FddeMetC) and / or ß-L-3 "-azido-2", 3 "-dideoxy-5-methylcytidine (L-ddMetC) and
  • ⁇ -L-5-methyl-deoxycytidine L-MetCdR
  • ⁇ -L-2 ", 3" -dideoxy-5-methylcytidine L-ddMetC
  • ⁇ -L-2 ", 3" -didehydro-2 are particularly preferred ", 3" -dideoxy-5-methylcytidine (L-ddeMetC), ß-L-arabinofuranosyl-5-methylcytosine (L-AraMetC) and ß-L-2 ", 3" -idehydro-2 ", 3” -dideoxy -2 "- fluoro-5-methylcytidine (L-FddeMetC), but also ß-L-2” - fluoroarabinofuranosyl-5-methylcytosine (L-FMAC) and ß-L-3 "- azido-2", 3 "- dideoxy-5-methylcytidine (L-AzMetdC).
  • the compounds according to the invention are prepared by processes known per se by condensation of the sugar part and heterocycle or by modification of the L-ribosyl radical.
  • the preferred compounds are particularly suitable for the following reasons.
  • the preferred compounds are particularly effective in inhibiting the multiplication of DNA viruses at the level of virus-specific transcription or translation.
  • the substances can influence the multiplication of viruses by inhibiting the enzyme reverse transcriptase or by breaking the growing DNA chain.
  • the structures according to the invention can cause the separation of a base pair and thus a wrong association or structural shift in the growing DNA chain or they prevent the formation of an RNA-DNA hybrid and can thus lead to chain termination or to the inhibition or modification of the viral replica - ions.
  • nucleoside according to the invention can have an inhibiting effect because the nucleoside according to the invention introduces multiple mutations into the subsequent polymerization and accumulation cycles, various such mutations for inhibiting the virus to lead.
  • the structures according to the invention - insofar as they are not a chain terminator - or incorporated into the DNA produce an inhibitory effect by binding to the active or allosteric binding site of the reverse transcriptase and thereby a competing, a non- competitive or non-competitive inhibition.
  • the nucleosides according to the invention naturally had a very broad therapeutic spectrum.
  • nucleosides according to the invention can preferably also be used in combination therapies, including a wide variety of combinations with known therapeutic agents and pharmaceutically acceptable carriers.
  • veterinary applications are also possible, as are feed additives for all vertebrates. Use in humans is particularly preferred.
  • the nucleosides according to the invention can be used particularly preferably for use as medicaments.
  • the nucleosides can be used alone, as a salt or derivative or as a composition.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
  • suitable acids include hydrogen chloride, hydrogen bromide, sulfur, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, milk, salicylic, amber, p-toluenesulfonic, wine, vinegar, Citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic and benzenesulfonic acids.
  • Preferred acids include hydrochloric, sulfuric, methanesulfonic and ethanesulfonic acids. Methanesulfonic acid is most preferred.
  • Other acids such as oxalic acid, although not themselves pharmaceutically acceptable, can be used in the preparation of salts which are useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
  • Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and N- (C ⁇ alkyl) 4 + - salts.
  • alkali metal e.g. sodium
  • alkaline earth metal e.g. magnesium
  • ammonium e.g. sodium
  • N- (C ⁇ alkyl) 4 + - salts e.g. sodium
  • N- (C ⁇ alkyl) 4 + - salts preferably those that result in the formation of stable compounds.
  • stable refers to compounds which have a stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time for the purposes described in detail herein to be useful (for example, therapeutic or prophylactic administration to a mammal or for use in affinity chromatography applications).
  • such compounds are stable at a temperature of 40 ° C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. Included among such acid salts are, for example, the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, citrate, camphorate, camphorsulfonate, cyclopentane propionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glycophosphate, gluco-sulfate Heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palate, pectinate, persulfate, 3-phenylpropionate, picrate, piquate, thiocyan
  • the invention also relates to nucleic acids which contain one or more nucleosides according to the invention as a building block.
  • nucleic acids can be prepared by methods known to the person skilled in the art, it is preferred that the nucleic acids according to the invention are composed of 2 to 5000, preferably 10 to 100, nucleoside units. particularly preferably from 20 to 40 nucleoside building blocks.
  • the nucleic acids according to the invention can preferably be used as antiviral, antibacterial or fungicidal agents, preferably as antiviral agents, in particular against hepatitis infections.
  • anti-sense nucleic acids the nucleic acids according to the invention hybridize with the DNA of the virus and thus inhibit the transcription of the virus DNA.
  • the nucleic acids can be used in particular as agents against hepatitis B, but also herpes, HIV and others, since they can advantageously be broken down only to a limited extent or with difficulty by the cell's own restriction enzymes.
  • the synthetic nucleic acids or anti-sense nucleic acids of the invention may be in the form of a therapeutic composition or formulation that can be used to inhibit DNA replication in a cell and in the treatment of human hepatitis infections and accompanying diseases in an animal. They can be used as part of a pharmaceutical composition in combination with a physiologically and / or pharmaceutically acceptable carrier.
  • a pharmaceutical composition in combination with a physiologically and / or pharmaceutically acceptable carrier.
  • the properties of the vehicle will depend on the route of administration.
  • Such a composition can contain, in addition to the synthetic nucleic acid and the carrier, diluents, fillers, salts, buffers, stabilizers, solvents and other known materials.
  • the pharmaceutical composition according to the invention can also contain other active factors and / or substances which increase the inhibition of HBV expression.
  • combinations of synthetic nucleic acids can be used in the pharmaceutical compositions according to the invention.
  • the pharmaceutical composition according to the invention can also other chemotherapeutic agents for the treatment of liver cancer.
  • additional factors and / or substances can be incorporated into the pharmaceutical composition in order to produce a synergistic effect with the synthetic nucleic acids according to the invention or to reduce side effects of the synthetic nucleic acids according to the invention.
  • the synthetic nucleic acids according to the invention can be incorporated into formulations of a specific anti-HBV or anti-cancer factor and / or substance for reducing the side effects of the anti-HBV factor and / or substance.
  • the pharmaceutical composition according to the invention can be in the form of a liposome in which the synthetic nucleic acids according to the invention, in addition to other pharmaceutically acceptable carriers with phiphatic substances such as lipids, which are in an aggregation form as micelles, insoluble monolayers, liquid crystals or lamella layers which are in a aqueous solution are combined.
  • Suitable lipids for a liposomal formulation include, but are not limited to, monoglycerides, diclycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids and the like.
  • Such liposomal formulations are prepared in a manner known per se and are known to the person skilled in the art.
  • the pharmaceutical composition of the invention may further contain other lipid carriers such as lipofectamine or cyclodextrins and the like, thereby enhancing the delivery of the nucleic acids to the cells, or may contain sustained release polymers.
  • the invention also relates, if appropriate, to a pharmaceutical composition which comprises at least one nucleoside according to the invention and / or a nucleic acid according to the invention together with customary auxiliaries, preferably carriers, adjuvants and / or vehicles.
  • a pharmaceutical agent in the sense of the invention is any agent in the field of medicine that can be used in the prophylaxis, diagnosis, therapy, follow-up or follow-up treatment of patients who have come into contact with viruses, including hepatitis viruses, in such a way that at least temporarily established a pathogenic modification of the overall condition or the condition of individual parts of the organism.
  • the pharmaceutical agent in the sense of the invention to be a vaccine, an immunotherapeutic or an immunoprophylactic.
  • the pharmaceutical agent in the sense of the invention can comprise the nucleosides according to the invention or the nucleosic acids according to the invention and / or an acceptable salt or components thereof.
  • These can be, for example, salts of inorganic acids, such as phosphoric acid, or salts of organic acids. It is also possible that the salts are free from carboxyl groups and have been derived from inorganic bases, such as sodium, potassium, ammonium, calcium or iron hydroxides, or from organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol , Histidine and others.
  • liquid carriers are sterile aqueous solutions which do not comprise any further materials or active ingredients, such as water or those which comprise a buffer such as sodium phosphate with a physiological pH or a physiological saline solution or both, such as phosphate - buffered sodium chloride solution.
  • a buffer such as sodium phosphate with a physiological pH or a physiological saline solution or both, such as phosphate - buffered sodium chloride solution.
  • Other liquid carriers may include more than just a buffer salt, such as sodium and potassium chloride, dextrose, propylene glycol, polyethylene glycol, or others.
  • Liquid compositions of the pharmaceutical compositions can additionally comprise a liquid phase, also with the exclusion of water. Examples of such additional liquid phases are glycerol, vegetable oils, organic esters or water-oil emulsions.
  • the pharmaceutical composition or the pharmaceutical composition typically contains at least 0.1% by weight of the nucleosides or nucleic acids according to the invention, based on the entire pharmaceutical composition.
  • the respective dose or the dose range for the administration of the pharmaceutical agent according to the invention is large enough to achieve the desired prophylactic or therapeutic anti-viral effect.
  • the dose should not be chosen so that undesirable side effects dominate.
  • the dose will vary with the age, constitution, gender of the patient and, of course, the severity of the disease.
  • the individual dose can be set in relation to the primary disease as well as in relation to the occurrence of additional complications. The exact one
  • Dose can be determined by a person skilled in the art using known means and methods, for example by determining the virus titer depending on the dose or depending on the vaccination schedule or the pharmaceutical carrier and the like.
  • the dose can be selected individually depending on the patient.
  • a dose of the pharmaceutical agent that is still tolerated by the patient can be one whose range in the plasma or in individual organs is locally in the range from 0.1 to 10000 ⁇ M, preferably between 1 and 100 ⁇ M.
  • the dose of the pharmaceutical agent that is still tolerated by the patient can be one whose range in the plasma or in individual organs is locally in the range from 0.1 to 10000 ⁇ M, preferably between 1 and 100 ⁇ M.
  • the dose of the pharmaceutical agent that is still tolerated by the patient can be one whose range in the plasma or in individual organs is locally in the range from 0.1 to 10000 ⁇ M, preferably between 1 and 100 ⁇ M.
  • the dose of the pharmaceutical agent that is still tolerated by the patient can be one whose range in the plasma or
  • Dose can also be calculated in relation to the patient's body weight.
  • a typical dose of the pharmaceutical agent would have to be set in a range between 0.1 ⁇ g to 100 ⁇ g per kg body weight, preferably between 1 and 50 ⁇ g7kg.
  • biopolymers are known to the person skilled in the art which can release nucleosides or nucleic acids in a desired manner.
  • Such a gel can contain, for example, 1 to 1000 ⁇ g of the compounds according to the invention or the pharmaceutical agent per ml of gel composition, preferably between 5 to 500 ⁇ g / ml and particularly preferably between 10 and 100 mg / ml.
  • the therapeutic agent is administered as a solid, gel-like or liquid composition.
  • the pharmaceutical agent can preferably further comprise one or more additional agents from the group of antiviral, fungicidal or antibacterial agents and / or immune stimulators.
  • the antiviral agent is preferably protease inhibitors and / or reverse transcriptase inhibitors.
  • the immune stimulators are preferably bropirimine, anti-human alpha-interferon antibodies, IL-2, GM-CSF, interferons, diethyldithiocarbamate, tumor necrosis factors, naltrexone, tuscarasol and / or rEPO.
  • the carriers are selected from the group comprising fillers, extenders, binders, humectants, disintegrants, solution retarders, absorption accelerators, wetting agents, adsorbents and / or lubricants.
  • the fillers and extenders are preferably starches, milk sugar, cane sugar, glucose, mannitol and silica, the binder, preferably carbomethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, the humectant, preferably glycerol, and the disintegrant, preferably Agar-agar, calcium carbonate and sodium carbonate, in the solution retarder preferably paraffin and in the absorption accelerator preferably quaternary ammonium compounds, in the wetting agent preferably cetyl alcohol and glycerol monostearate, in the adsorbent preferably kaolin and bentonite and in the lubricant preferably talc, calcium and magnesium stearate and solid polyethylene glycols or mixtures of the listed substances.
  • the binder preferably carbomethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, the humectant, preferably glycerol, and the disintegrant, preferably Agar-a
  • the invention also relates to vectors, cells and / or
  • Organisms which have a nucleoside according to the invention, a nucleic acid according to the invention and / or a pharmaceutical agent according to the invention.
  • the invention also relates to the use of the nucleosides according to the invention, the nucleic acids according to the invention and / or the pharmaceutical composition according to the invention in the prophylaxis or therapy of a viral, bacterial, fungicidal and / or parasitic infection or cancer.
  • viruses can trigger various tumors. The triggering of these tumors can be prevented prophylactically or treated therapeutically with the compounds according to the invention.
  • the structures according to the invention for example, in an anti-cancer combination therapy.
  • the person skilled in the art is furthermore aware that, in addition to the viruses, the bacteria associated with the viral diseases or occurring in isolation represent a medical problem. numerous Bacteria are resistant to the known antibacterial agents.
  • the compounds according to the invention can also be used for the prophylaxis and treatment of bacterial infections. Furthermore, the compounds according to the invention can also be used for the production of medicaments for the treatment and prophylaxis of bacterial infections.
  • These can preferably be bacteria of the genera Escherichia coli, Salmonella spp., Shigella flexneri, Citrobacter freundii, Klebsiella pneumoniae, Vibrio spp., Haemophilus influenzae, Yersinia enterolitica, Pasturella haemolytica, and Proteus spp. act.
  • the invention relates to the use of the compounds according to the invention for preventing the incorporation of other nucleosides during transcription in a growing DNA chain, for preventing the formation of a DNA-RNA hybrid, for separating a base pair or for competing inhibition of a growing DNA chain.
  • the compounds according to the invention are used to prophylactically or therapeutically treat viral diseases which are combined with one of the following viruses or a combination thereof: hepatitis virus, HIV, bovine immunodeficiency virus, human T- Cell Leukemia Virus, Fine Immunodeficiency Virus, Caprines Arthritis Encephalitis Virus, Equine Infectious Anemia Virus, Ovine Maedi-Visna Virus, Visna-Lentivirus and others.
  • DNA viruses are preferably treated. It is known to the person skilled in the art that such viral infections can occur in combination with bacterial, fungicidal, parasitic or other infections. Use is particularly preferred when the hepatitis virus is a hepatitis B or a hepatitis D virus.
  • the pharmaceutical agent according to the invention comprises HBV DNA polymerase inhibitors.
  • the pharmaceutical agent for the treatment - in particular of Hepatistis B - contains other effective anti-HBV agents, preferably PMEA (adefovir dipivoxil), famciclovir, penciclovir, diaminopurine dioxolane (DAPD), clevudine (L-FMAU ), Entecavir, interferon or thymosin 1 and / or inhibitors of nucleocapsid formation, especially heteroaryl pyrimidines.
  • the agents are pegylated.
  • the agent contain additional agents which are able to switch off the function of cellular proteins which are essential for the multiplication of HBV.
  • agents against viruses which are resistant to lamivudine or another cytosine nucleoside such as e.g. B. Emtricitabine (L-FTC), L-ddC or L-ddeC.
  • This agent can preferably also be used against liver cancer diseases which were triggered by chronic hepatitis, in particular by HBV.
  • ⁇ -L-nucleosides increase the effect of other pharmaceutical agents, non-additive, additive or synergistically increased the therapeutic index and / or that of the Reduce the risk of toxicity associated with each compound.
  • a preferred HIV in the sense of the invention is HIV-1 with subtypes A to J (HIV-1 group M) according to the subtype subdivisions of the prior art and the remotely related HIV-0 (HIV-1 group O).
  • Preferred main subtypes are 1A, IB, IC and ID.
  • the subtypes 1E, IG and 1H are closely related to HIV-IA and are also preferred.
  • the preferred HIV-IA and IC as well as IB and ID show homologies with one another.
  • the likewise preferred HIV-0 is more heterogeneous in the individual virus isolates than HIV-1.
  • a division into subtypes cannot be made.
  • HIV-2 which can be divided into subtypes A to E. It has a milder pathogenicity than HIV-1 and has therefore spread more slowly.
  • the genetic variability leads to changes in the external coat proteins. The influence on cell tropism and the question of how far this is associated with different transmission probabilities has not been sufficiently clarified. Treatment of double infections with different subtypes (e.g. B and
  • the nucleosides according to the invention are used in combination with 3-deazauridine.
  • Combined use can mean simultaneous or delayed administration.
  • the combined administration can take place, for example, in a combination agent.
  • the combination means in the sense of the invention can, for example, be such that in a solution or in a solid such as a tablet, nucleosides according to the invention and 3-deazauridine are contained together.
  • the ratio of nucleosides according to the invention and 3-deazauridine can vary freely. A ratio of nucleosides according to the invention and 3-deazauridine in the range from 1: 10,000 to 10,000: 1 is preferred. Within this range, the ratio of nucleosides according to the invention and 3-deazauridine can vary depending on the desired application.
  • the at least two components - nucleosides according to the invention and 3-deazauridine - can also be introduced together into a solution or a solid so that they are released with a time delay.
  • the combination agent in the sense of the invention can also consist of two separate solutions or two separate solids, the one solution or one solid essentially comprising 3-deazauridine and the other solution or the other solid essentially comprising nucleosides according to the invention. It is possible that the two solutions or solids are associated with a common or with separate carriers. The two solutions and / or the two solids can be present, for example, in a capsule as a common carrier. Such a formulation of the combination agent according to the invention is particularly advantageous when the nucleosides and the 3-deazauridine administration according to the invention are to be carried out with a time lag.
  • the organism is first brought into contact with the nucleosides according to the invention, for example by infusion or by oral administration, in order then to be brought into contact with the other constituent of the combination agent at a later time.
  • the combination agent it is also possible for the combination agent to be provided using conventional pharmaceutical methods and processes in such a way that the organism first with 3-deazauridine and then with the nucleosides according to the invention are brought into contact. It is therefore preferred to sequentially bring the organism into contact with the components of the combination agent.
  • the time period between the administration of the two components of the combination agent according to the invention or the first release of nucleosides or 3-deazauridine according to the invention depends on the age, gender, overall constitution of the patient, the disease or other parameters, for example by the treating doctor can be determined by preliminary tests.
  • the compounds according to the invention are used as a prodrug, as a feed additive and / or as a drinking water additive, the use as a feed additive and / or as a drinking water additive being preferred in veterinary medicine.
  • a prodrug contains its active ingredient in the form of an inactive precursor metabolyte.
  • a prodrug contains its active ingredient in the form of an inactive precursor metabolyte.
  • Carrier-prodrug systems contain the active substance as such, bound to a masking group that stands out can split off the simplest possible controllable mechanism.
  • the function according to the invention of masking groups in the nucleosides according to the invention is the neutralization of the negative charge on the phosphate residue for improved cell uptake. If the nucleosides according to the invention are used with a masking group, this can also influence other pharmacological parameters, such as oral bioavailability, tissue distribution, pharmacokinetics and stability to non-specific phosphatases.
  • the delayed release of the active ingredient can also have a depot effect. Modified metabolism can also occur, resulting in higher drug efficiency or organic specificity.
  • the masking group or a linker group which binds the masking group to the active ingredient are selected such that the nucleoside prodrug has sufficient hydrophilicity to be dissolved in the blood serum, sufficient chemical and enzymatic Has stability to get to the site of action and has such hydrophilicity that it is suitable for diffusion-controlled membrane transport. Furthermore, it should enable a chemically or enzymatically induced release of the active substance within a reasonable period of time and of course the released auxiliary components should not have any toxicity.
  • the nucleoside can also be regarded as a prodrug without a mask or a linker and a mask, since the viral DNA polymerase-inhibiting structure is an energy-rich triphosphate, which is first extracted from the incorporated nucleoside by enzymatic and biochemical processes Cell must be provided.
  • the compounds according to the invention are used as a gel, powder, powder, tablet, slow-release tablet, premix, emulsion, infusion formulation, drops, concentrate, granules, syrup, pellet, bolus, capsule, aerosol, spray and / or Inhaled prepared and / or used in this form.
  • the tablets, dragées, capsules, pills and granules can be provided with the usual coatings and casings, optionally containing opacifying agents, and can also be composed such that they release the active ingredient (s) only or preferably in a certain part of the intestinal tract, possibly with a delay , whereby polymer substances and waxes can be used as embedding compositions.
  • compositions of this invention can preferably be used for oral administration in any orally acceptable dosage form, including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • carriers that are used frequently include lactose and corn starch.
  • Lubricants, such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • the active ingredient (s) can optionally also be in microencapsulated form with one or more of the above-mentioned excipients.
  • suppositories can contain the usual water-soluble or water-insoluble carriers, for example polyethylene glycols, fats, for example cocoa fat and higher esters (for example C 14 ⁇ alcohol with C 16 fatty acid) or mixtures of these substances).
  • ointments, pastes, creams and gels can contain the usual excipients, for example animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures of these substances ,
  • powders and sprays can contain the usual carriers, for example lactose, talc, silica, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these.
  • Sprays can also contain the usual blowing agents, for example chlorofluorocarbons.
  • solutions and emulsions can include the customary carriers such as solvents, solubilizers and emulsifiers, for example water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular Contain cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil, glycerin, glycerinfor al, tetrahydofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances.
  • solvents such as solvents, solubilizers and emulsifiers
  • solvents such as solvents, solubilizers and emulsifiers
  • solvents such as solvents, solubilizers and emulsifiers
  • solvents such as solvents, so
  • suspensions can contain the usual excipients such as liquid diluents
  • liquid diluents examples include water, ethyl alcohol, propylene glycol, suspending agents, for example ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar agar and tragacanth or mixtures of these substances.
  • the medicaments can be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oily suspension.
  • This suspension can also be formulated using methods known in the art using suitable dispersing or wetting agents (such as Tween 80) and suspending agents.
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally compatible diluent or solvent, for example as a solution in 1,3-butanediol.
  • Acceptable vehicles and solvents that can be used include mannitol, water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, non-volatile oils are usually used as a solvent or suspending medium.
  • Any mild non-volatile oil including synthetic mono- or diglycerides, can be used for this purpose.
  • Fatty acids such as oleic acid and its glyceride derivatives, can be used in the manufacture of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated forms.
  • These oil solutions or suspensions can also contain a long-chain alcohol such as Ph.Helv., Or a similar alcohol as a diluent or dispersant.
  • the formulation forms mentioned can also contain colorants, preservatives and additives which improve the smell and taste, for example peppermint oil and eucalyptus oil, and sweeteners, for example saccharin.
  • the active Substances of the formula (I) or (II) should preferably be present in the listed pharmaceutical preparations in a concentration of approximately 0.1 to 99.5, preferably approximately 0.5 to 95% by weight of the total mixture.
  • the listed pharmaceutical preparations can also contain further active pharmaceutical ingredients.
  • the pharmaceutical preparations listed above are prepared in a customary manner by known methods, for example by mixing the active ingredient (s) with the carrier (s).
  • the preparations mentioned can be used in humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, subcutaneously), intracisternally, intravaginally, intraperitoneally, locally (powder, ointment, drops) and for the treatment of infections in cavities, body cavities.
  • Injection solutions, solutions and suspensions for oral therapy, gels, infusion formulations, emulsions, ointments or drops can be considered as suitable preparations.
  • ophthalmic and dermatological formulations, silver and other salts, ear drops, eye ointments, powder or solutions can be used.
  • suitable formulations can also be ingested through feed or drinking water.
  • Gels, powders, powders, tablets, prolonged-release tablets, premixes, concentrates, granules, pellets, tablets, boluses, capsules, aerosols, sprays, inhalants can also be used in humans and animals.
  • the compounds according to the invention can be used in other carrier materials such as for example plastics, (plastic chains for local therapy), collagen or bone cement.
  • the compounds according to the invention ie the nucleoside according to the invention, the nucleic acid according to the invention, the pharmaceutical compositions or vectors according to the invention, cells and organisms in a concentration of 0.1 to 99.5, preferably 0 , 5 to 95, particularly preferably from 20 to 80 wt .-% in a preparation. That is, the compounds according to the invention are present in the pharmaceutical preparations listed above, for example tablets, pills, granules and others, preferably in a concentration of 0.1 to 99.5% by weight of the total mixture.
  • the active ingredient narrow, i.e.
  • the amount of a compound according to the invention, which is combined with the carrier materials to produce a single dosage form will be able to vary by the person skilled in the art depending on the host to be treated and the particular mode of administration.
  • the proportion of the active compound in the preparation can be changed so that a maintenance dose is available.
  • the dose or frequency of administration, or both as a function of symptoms can then be reduced to a level at which the improved condition is maintained. If the symptoms have been relieved to the desired level, treatment should stop.
  • patients may need long-term interruption treatment after any recurrence of disease symptoms. Accordingly, the proportion of the compounds, that is to say their concentration, in the overall mixture of the pharmaceutical preparation as well as their composition or combination is variable and can be modified and adapted by the person skilled in the art on the basis of his specialist knowledge.
  • the compounds according to the invention have an organism, preferably a human or an animal, can be brought into contact in various ways. It is also known to the person skilled in the art that in particular the pharmaceutical compositions can be administered in different dosages.
  • the application should be carried out in such a way that the viral disease is combated as effectively as possible or the outbreak of such a disease is prevented by prophylactic administration.
  • the concentration and the type of application can be determined by a person skilled in the art through routine tests.
  • Preferred applications of the compounds according to the invention are oral application in the form of powder, tablets, juice, drops, capsules or the like, rectal application in the form of suppositories, solutions and the like, parenterally in the form of injections, infusions and solutions, inhalation of Vapors, aerosols and dusts and plasters as well as locally in the form of ointments, plasters, envelopes, rinses and the like.
  • the contacting of the compounds according to the invention is preferably carried out prophylactically or therapeutically.
  • the infection with the viruses mentioned should at least be prevented in such a way that, after individual viruses have penetrated, for example into a wound, further multiplication thereof is greatly reduced or that viruses which have penetrated are almost completely killed off.
  • the patient is already infected and the viruses already in the body are said to either be killed or to be prevented from multiplying.
  • Further preferred forms of application for this are, for example, subcutaneous, sublingual, intravenous, intramuscular, intraperitoneal and / or topical.
  • the application scheme, the adjuvant selection and the like can be obtained, for example, by removing Serum alliquots from the patient, i.e. human or animal, and testing for the presence of viruses, i.e. determining the virus titer, are determined in the course of the treatment protocol.
  • the condition of the liver but also the amount of T cells or other cells of the immune system, can be determined in a conventional manner to provide an overview of the patient's immunological constitution and in particular the constitution of metabolically important organs. especially the liver.
  • the clinical condition of the patient can be observed for the desired effect, in particular the anti-infectious, preferably the antiviral effect.
  • HIV or other diseases can be associated with further, for example bacterial or fungicidal, infections or tumor diseases
  • the patient can be modified and treated further with agents according to the invention or other known medicaments, from which an improvement in the overall constitution can be expected.
  • agents according to the invention or other known medicaments, from which an improvement in the overall constitution can be expected.
  • injections for example intramuscularly or subcutaneously or into the blood vessels, are a further preferred route for the therapeutic administration of the compounds according to the invention.
  • the compounds can also be used in a total amount of 0.05 to 500 mg / kg body weight per 24 hours, preferably from 5 to 100 mg / kg body weight. This is advantageously a therapeutic amount that is used to prevent or improve the symptoms of a disorder or responsive, pathologically physiological condition.
  • the amount administered is sufficient to prevent or inhibit the infection or spread of the infectious agent, such as hepatitis B or HIV, in the recipient.
  • the effect of the compound according to the invention on the viruses mentioned with regard to their prophylactic or therapeutic potential can be seen, for example, as an inhibition of the virus infection, as an inhibition of syncytomy, as an inhibition of the fusion between virus and target membrane, as a reduction or stabilization of the rate of virus replication in an organism or otherwise.
  • the therapeutic effect can consist, for example, in that certain antiviral drugs work better as a desired side effect through the application of the compounds according to the invention, or the number of side effects of these drugs is reduced by reducing the dose.
  • the therapeutic effect also includes direct action on the viruses in a host.
  • the activity of the compounds according to the invention is not limited to eliminating the viruses, but rather encompasses the entire spectrum of advantageous effects in prophylaxis and therapy.
  • the dose will depend on the age, health and weight of the recipient, the degree of the disease, the type of simultaneous treatment necessary, the frequency of treatment and the type of effects desired and the side effects.
  • the daily Doses of 0.05 to 500 mg / kg body weight can be used once or several times to get the desired results.
  • Daily dose levels are useful in the prevention and treatment of a viral infection including hepatitis B infection.
  • pharmaceutical agents are typically used for administration approximately 1 to 7 times per day or alternatively or additionally as a continuous infusion. Such administrations can be used as chronic or acute therapy.
  • the amounts of active ingredient that are combined with the carrier materials to produce a single dosage form can of course vary depending on the host to be treated and the particular mode of administration.
  • the target dose it is preferred to distribute the target dose over 2 to 5 applications, 1 to 2 tablets with an active substance content of 0.05 to 500 mg / kg body weight being administered for each application.
  • an active substance content of 0.05 to 500 mg / kg body weight being administered for each application.
  • a higher active substance content for example up to a concentration of up to 5000 mg / kg. For example, you can
  • Tablets can also be delayed, which reduces the number of applications per day to 1 to 3.
  • the active substance content of the retarded tablets can be 3 to 3000 mg. If, as stated, the active ingredient is administered by injection, it is preferred to bring the host into contact with the compounds according to the invention 1 to 8 times a day or by continuous infusion, amounts of 4 to 4000 mg per day being preferred are. The preferred total amounts per day have proven to be advantageous in human medicine and in veterinary medicine. It may be necessary to deviate from the doses mentioned, depending on the type and body weight of the host to be treated, the type and severity of the disease, the type of preparation for the administration of the medicament and the period or Interval within which the administration takes place.
  • the compounds according to the invention are administered in a single dose of 1 to 80, in particular 3 to 30 mg / kg body weight used.
  • the amount of the single dose per application can be varied by the person skilled in the art on the basis of his specialist knowledge.
  • the compounds used according to the invention can also be given in the individual concentrations and preparations mentioned together with the feed or with feed preparations or with the drinking water in veterinary medicine.
  • a single dose preferably contains the amount of active ingredient which is administered in one application and which usually corresponds to a whole, half a daily dose or a third or a quarter of a daily dose.
  • the dosage units can accordingly preferably contain 1, 2, 3 or 4 or more single doses or 0.5, 0.3 or 0.25 of a single dose.
  • the daily dose of the compounds according to the invention is preferably divided into 2 to 10 applications, preferably to 2 to 7, particularly preferably to 3 to 5 applications.
  • a permanent infusion of the agents according to the invention is of course also possible.
  • 1 to 2 tablets are given for each oral application of the compounds according to the invention.
  • the tablets according to the invention can be provided with coatings and casings known to the person skilled in the art and can also be composed in such a way that they only release the active ingredient (s) in a certain part of the host, if preferred.
  • the compounds according to the invention can be used with at least one other known pharmaceutical agent.
  • the compounds according to the invention can be used in a prophylactic or therapeutic combination in conjunction with the known medicaments.
  • These combinations can be administered together, for example in a uniform pharmaceutical formulation, or separately, for example in the form of a combination of tablets, injection or other medicaments, which are administered at the same or at different times, with the aim of achieving the desired one to achieve prophylactic or therapeutic effects.
  • These known agents can be agents which increase the action of the nucleosides according to the invention. In particular, it has been found in the antibacterial sector that a wide variety of antibiotics improve the action of nucleosides.
  • an additional embodiment of the invention relates to a combination in which the second agent is at least one of the aforementioned antiviral or antibacterial agents or classes of agents. It should also be noted that the compounds and Combinations can also be used in conjunction with immunomodulatory treatments and therapies.
  • an optimal ratio of the compound (s) according to the invention to one another and / or to other therapeutic or activity-increasing agents such as transport inhibitors, metabolism inhibitors, inhibitors for renal excretion or glucuronidation, such as sample oath, aceta inophene, aspirin, lorazepan, cimetidine, ranitidine , Colifibrate, indomethacin, ketoprofen, naproxen etc.
  • An optimal ratio is defined as the ratio at which the compound (s) according to the invention with another therapeutic agent or agents is such that the overall therapeutic effect is greater than the sum of the effects of the individual therapeutic agents.
  • the optimal ratio is usually found when the means are in the ratio of 10: 1 to 1:10, 20: 1 to 1:20, 100: 1 to 1: 100 and 500: 1 to 1: 500. Occasionally, a negligible amount of a therapeutic agent will suffice to increase the effectiveness of one or more other agents.
  • the use of the compounds according to the invention in combinations is particularly useful in order to reduce the risk of developing resistance.
  • the compounds according to the invention such as the nucleosides or nucleic acids, can of course be used in combination with other known anti-viral agents. Such means are known to the person skilled in the art.
  • the compounds according to the invention can accordingly be administered with all conventional agents, in particular other drugs, which are available for use in connection with, in particular, hepatitis drugs, either as individual drugs or in a combination of drugs. They can be administered alone or in combination with them.
  • the compounds according to the invention are administered with the other known pharmaceutical agents in a ratio of about 0.005 to 1. It is preferred to administer the compounds according to the invention with, in particular, virus-inhibiting agents in a ratio of from 0.05 to about 0.5 part to about 1 part of the known agents. These can also be antitumor or antibacterial agents.
  • the pharmaceutical composition can be in substance or as an aqueous solution together with other materials such as preservatives, buffer substances, agents which are intended to adjust the osmolarity of the solution, etc.
  • the invention also relates to the use of the nucleic acids according to the invention as anti-sense nucleic acids, in particular in antiviral therapy.
  • the person skilled in the art knows that he can use nucleic acids as anti-sense nucleic acids.
  • the nucleic acid according to the invention preferably serves to prevent the hybridization of the RNA during translation by hybridizing the RNA of the viruses with the nucleic acids according to the invention.
  • the nucleic acids according to the invention can be used in particular as agents against hepatitis B, since they cannot be broken down by the cell's own restriction enzymes or only with difficulty.
  • the nucleic acid according to the invention hybridizes with the DNA of the hepatitis B virus and, in addition to translation, also makes transcription to the virus DNA more difficult.
  • the nucleosides according to the invention and the nucleic acids according to the invention can be used for the production of pharmaceutical agents. It is thus possible for the teaching according to the invention also to be a method for treating a Viral, bacterial, fungicidal and / or parasitic infection or cancer relates, wherein the nucleosides and / or nucleic acids according to the invention are brought into contact with an organism.
  • the treatment in the sense of the invention includes the prophylactic as well as the therapeutic treatment.
  • the compounds according to the invention can preferably be used to protect organisms, in particular human patients, against a virus infection during a special event, such as childbirth, or for an extended period of time in a country where there is a high risk of infection for hepatitis B. become.
  • the compounds of the invention can then be used alone or with other prophylactic or other antiviral agents that enhance the effectiveness of each agent.
  • the nucleosides according to the invention can be easily adsorbed, preferably after oral administration, into the bloodstream of mammals, in particular human mammals.
  • the compounds advantageously exhibit good water solubility and consistent oral availability.
  • the good oral availability makes the compounds according to the invention excellent agents for orally administered treatment and prevention courses against a viral infection, in particular a hepatitis B infection.
  • the compounds according to the invention are not only biologically available orally, but they also advantageously have a high therapeutic index, which above all measures the toxicity against the antiviral effect.
  • the compounds according to the invention are more effective than selected known antiviral agents at lower dose levels and avoid the toxic effect associated with these drugs.
  • the potential of the compound according to the invention to be delivered in doses " which far exceed its effective antiviral proportions is particularly evident. partial in slowing down or preventing the possibility of developing resistant variants.
  • compounds according to the invention can be used in a healthy, but also in a virally infected, in particular infected with a hepatitis B virus, either as a single agent or together with other antiviral agents, which preferably interfere with the replication cycle of hepatitis viruses, be used.
  • the compounds according to the invention are used in prophylaxis and therapy according to the routes known to the person skilled in the art.
  • each agent used that is to say the known compounds and the compound according to the invention, has an additive, non-additive or synergistic effect in inhibiting virus replication, since it can advantageously be provided that each agent acts at a different point in the replication of the viruses.
  • the method of such combination therapies can also advantageously prevent the dosage of a conventional antiviral agent for which a desired therapeutic or prophylactic effect would be required compared (when the agent is administered alone).
  • Such combinations of the method according to the invention for the treatment of viral diseases can reduce or eliminate the side effects of conventional therapies with individual antiviral agents, wherein they advantageously do not interfere with the antiviral effect of these agents, but rather increase synergistically. These combinations reduce the potential for resistance to single agent therapy while advantageously minimizing the associated toxicity. These combinations can also increase the effectiveness of the conventional agent without increasing the associated toxicity.
  • the compounds according to this invention, together with other antiviral or antibacterial or fungicidal agents, in an additive or synergistic manner prevent the replication of the genetic material of viruses.
  • Preferred combination therapies include administration of a compound of the invention with ACTddi, ddC, d4T, 3TC, or a combination thereof.
  • the compounds according to the invention can also be used together with immunomodulators or immunostimulators; preferred immunomodulators or immunostimulators are: propirimine, anti-human ⁇ -interferon antibodies, IL-2, GM-CSF, interferon ⁇ , diethyldithiocarbamate, tumor necrosis factor, naltrexone, Tuscarasol, rEPO and antibiotics such as pentamidine isethionate; but also agents that prevent or fight malignant tumors associated with viral diseases.
  • preferred immunomodulators or immunostimulators are: propirimine, anti-human ⁇ -interferon antibodies, IL-2, GM-CSF, interferon ⁇ , diethyldithiocarbamate, tumor necrosis factor, naltrexone, Tuscarasol, rEPO and antibiotics such as pentamidine isethionate; but also agents that prevent or fight malignant tumors associated with viral diseases.
  • preferred immunomodulators or immunostimulators are:
  • Pharmaceutically acceptable carriers, adjuvants and ve Products that can be used in the medicaments of this invention include ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d ⁇ -tocopherol polyethylene glycol 1000 succinate, or other similar polymeric delivery matrices, serum proreins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acids, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogenphosphate, potassium hydrogenphosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisiliconosulfonate, polyvinyl trisiliconosulfonate, polyvinyl sulfonate, polyvinylsulfonate , Polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes
  • Cyclodextrins such as ⁇ -, ⁇ -, and ⁇ -cyclodextrin, or chemically modified derivatives, such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- ⁇ -cyclodextrins, or other solubilized derivatives can also be used advantageously, to increase the delivery of the compounds of the invention.
  • the compounds according to the invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. Oral administration or administration by injection is preferred as the form of contacting.
  • the pharmaceutical compositions of this invention can contain any conventional non-toxic pharmaceutically acceptable carrier, adjuvant or vehicle.
  • the pH of the formulation can be adjusted with pharmaceutically acceptable acids, bases or buffers to increase the stability of the formulated compound or its delivery form.
  • parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intra- muscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion procedures in the form of contacting.
  • the invention also relates to a kit which comprises the compounds according to the invention, optionally with information about combining the contents of the kit.
  • the information on combining the contents of the kit relates to the use of the kit for the prophylaxis and / or therapy of diseases, in particular viral diseases.
  • the information can also relate, for example, to a therapy scheme, ie to a specific injection or application scheme, to the dose to be administered or something else.
  • the nucleoside analogs according to the invention have numerous advantages. Human and animal organisms have to deal with numerous pathogens in the course of their individual development. These pathogens can represent fungi, bacteria, but especially viruses. Every year, millions of people and farm animals worldwide contract viral diseases, with numerous of these infections being associated with significant health impairments. Diseases with the human immunodeficiency virus with the hepatitis viruses or HIV can sometimes lead to death if left untreated.
  • the very infectious viruses include the hepatitis B viruses (HBV), which can cause inflammation of the liver, which is regularly accompanied by damage to the liver cells.
  • HBV hepatitis B viruses
  • antiviral therapies have been developed in the prior art in order to be able to successfully fight viruses in a host organism - for example a human being or an agricultural product or pet.
  • Many of these therapies are chemotherapies that are intended to prevent the replication of pathogenic viruses in the host cell.
  • Various phases of replication such as adsorption, penetration, translation, transcription of the viral genes, replication of the nucleic acid and the assembly of the virus particles can be used as a point of attack for the so-called virus statics used here.
  • the virus adsorption inhibitors interact with cationic regions of the viral coat protein and thereby prevent association with the receptors of the potential host cell.
  • the inhibitors of virus-cell fusion do not already prevent the binding, but only the fusion with the host cell with the formation of a common membrane.
  • Another possibility is the inhibition of the penetration with release of the viral genome, as described in the prior art for Picorna viruses, for example. It is also possible to block the transcription and protein biosynthesis of the viruses.
  • the prior art also describes methods for inhibiting viral DNA polymerase. The inhibition of viral DNA polymerase is disclosed in the prior art, in particular for herpes viruses. The DNA
  • Herpesvirus polymerase has different functions. Among other things, it is responsible for introducing the viral genetic information of the genome of the host cell, for RNA-dependent DNA synthesis, for DNA-dependent DNA synthesis and has other tasks. Many of the Antiviral compounds successfully used today are nucleoside-analogous substances. however, their antiviral activity is particularly limited to herpes viruses.
  • nucleosides according to the invention avoid these listed disadvantages of the prior art.
  • the solvent is removed in vacuo, the dark residue obtained is dissolved in water (40 ml) and placed on a column (2 ⁇ 20 cm) which contains DOWEX 50 WX 8 (H + form). It is eluted first with water (500 ml) and then with 5% ammonia solution (800 ml). The ammoniacal eluate is evaporated to dryness in vacuo. The residue is purified by chromatography on silica gel with the upper phase of the solvent mixture ethyl acetate / i-propanol / water (4/1/2, v / v).
  • ß-L- Methyl deoxycytidine is obtained as a yellowish foam (1.3 g), from which 200 mg are branched off, dissolved in a little methanol and a few drops of methanolic HCl are added. The crystals which have separated out after some time are filtered off.
  • the hydrochloride of ß-L-methyldeoxycytidine thus obtained has a melting point of 151-153 ° C (dec.).
  • UV spectrum (H 2 0, pH 7) ⁇ max 281 n ( ⁇ 11644), ⁇ min 251 nm ( ⁇ 5448); (H 2 0, pH 1) ⁇ max 287 nm ( ⁇ 14770), ⁇ min 245 nm ( ⁇ 2238).
  • ß-L-5-methyldeoxycytidine (7.25 g, 30 mmol) is dissolved under an argon protective atmosphere in anhydrous dimethylformamide (200 ml) and treated with benzoic anhydride (7.5 g, 33 mmol) added. The reaction mixture is stirred for 24 hours at room temperature. The solvent is then removed in vacuo. The resulting residue is triturated with ether, filtered off, washed with ether and dried. 9.3 g of 1- (2-deoxy-ß-L-ribofuranosyl) - N-benzoyl-5-methylcytosine are obtained as a crude product.
  • UV spectrum H 2 0, pH 7
  • ⁇ max 278 nm ⁇ 10067
  • ⁇ min 253 ⁇ 5668
  • H 2 0, pH 1 ⁇ max 285 nm ( ⁇ 9240), ⁇ m ⁇ n 244 nm ( ⁇ 1628).
  • the melting point of the hydrochloride is 201-203 ° C (dec.).
  • UV spectrum H 2 0, pH 7) ⁇ max 281 nm ( ⁇ 11796), ⁇ min 250 nm ( ⁇ 4600); (H 2 0, pH 1) ⁇ ma ⁇ 288 nm ( ⁇ l4633), ⁇ mn 247 nm ( ⁇ 3800).
  • This compound is dissolved in pyridine (50 ml) with 1H-1, 2, 4-triazole (1.37 g; 15 mmol) and chlorophenyl dichlorophosphate (2.42 ml; 15 mmol) were added. The mixture remains at room temperature for four days. The pyridine is then removed in vacuo, the residue is dissolved in dioxane / 25% ammonia (50 ml; 3/1; v / v) and stored overnight at room temperature. The solvent is removed in vacuo, the residue obtained is dissolved in water (50 ml) and placed on a column (2 ⁇ 20 cm) which contains DOWEX 50 WX 8 (H + form).
  • the antiviral activity of the compounds according to the invention was investigated on HepG2 2.2.15 cells, a human hepatoblastoma cell line which the contains replication-competent HBV genome stably integrated and productively produces infectious progeny viruses (Seils et al., Proc Natl Acad Sei USA 1987, 84: 1005-1009). These cells were cultivated under the standardized conditions specified by Korba and Gerin and the amount of extracellular viral DNA was determined (Korba et al. Antiviral Res 1992, 19: 55-70).
  • HepG2 2.2.15 cells were seeded with a density of about 60% in 12-well plates and cultured in 10% FBS Dulbecco MEM to confluence. The medium was then switched to 2% FBS and the cells were cultured for a further 24 h.
  • the cells were treated with different concentrations of the compounds according to the invention.
  • the connections were also added to the medium every 24 hours.
  • the cell supernatants were centrifuged off and stored at -20 ° C. until analysis of the HBV DNA.
  • the extracellular viral DNA was amplified by PCR using the following primers (forward: 5 "-CTC CAG TTC AGG AAC AGT AAA CCC-3"; reverse: 5 "-TTG TGA GCT CAG AAA GGC CTT GTA AGT TGG CG-3 ".
  • the PCR products were separated on 1% agarose, stained with ethidium bromide and quantified with the Fluor-S TM Multimager (Biorad).
  • Table 1 The effectiveness of the ⁇ -L-5-methylcytidine nucleosides compared to 3TC (lamivudine) on HBV replication in HepG2 2.2.15 cells. The concentrations are shown which lead to a 50% reduction in HBV DNA in the medium of the cells (ED 50 values).
  • HBV DNA polymerase activity For the determination of the endogenous HBV DNA polymerase activity, about 60 ml of serum from patients with hepatitis B infections from Charite, Berlin (> 10 7 HBV Particles / ml) centrifuged at 3000 rpm, then the virus particles at 25,000 g, sedimented for 60 min, in 7 ml of TKM buffer (50 mM Tris-HCl, pH7, 5, 50 mM KC1, 5 mM MgCl 2 ) and taken up by a Sucrose gradients (0.3 M, 0.6 M, 0.9 M sucrose in 10 ml TKM buffer)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des analogues de nucléoside, des acides nucléiques et des agents pharmaceutiques les comprenant, ainsi que l'utilisation des analogues de nucléoside, des acides nucléiques et desdits agents pharmaceutiques à des fins de diagnostic, de prophylaxie ou de thérapie d'infections virales, bactériennes, fongicides et/ou parasitaires ou de cancers, en particulier d'infections hépatiques. L'invention concerne en outre un procédé de production d'analogues de nucléoside, ainsi qu'un coffret et son utilisation pour assurer la prophylaxie et le traitement d'affections virales, notamment d'infections hépatiques.
EP04786771A 2003-09-12 2004-09-13 Nucleosides b-l et leur utilisation comme agents pharmaceutiques pour traiter des affections virales Withdrawn EP1668023A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10342509 2003-09-12
DE10342510 2003-09-12
PCT/DE2004/002051 WO2005026186A1 (fr) 2003-09-12 2004-09-13 Nucleosides β-l et leur utilisation comme agents pharmaceutiques pour traiter des affections virales

Publications (1)

Publication Number Publication Date
EP1668023A1 true EP1668023A1 (fr) 2006-06-14

Family

ID=34314989

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04786771A Withdrawn EP1668023A1 (fr) 2003-09-12 2004-09-13 Nucleosides b-l et leur utilisation comme agents pharmaceutiques pour traiter des affections virales

Country Status (3)

Country Link
US (1) US20060217345A1 (fr)
EP (1) EP1668023A1 (fr)
WO (1) WO2005026186A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3066115B1 (fr) * 2017-05-10 2019-06-28 Universite de Bordeaux Comprimes de vecteurs d'acides nucleiques
EP3836941A4 (fr) 2018-08-14 2022-05-18 Tosk, Inc. Procédés et compositions pour le traitement de la mucosite
CN112839663A (zh) 2018-08-14 2021-05-25 托斯克公司 降低氟尿嘧啶诱发的毒性的方法和组合物
CN112770760A (zh) 2018-08-14 2021-05-07 托斯克公司 降低辐射诱发的毒性的方法和组合物
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2022010778A1 (fr) 2020-07-07 2022-01-13 Tosk, Inc. Inhibiteurs d'uridine phosphorylase pour traiter ou prévenir une maladie pulmonaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT61566A (en) * 1990-03-13 1993-01-28 Acic Canada Inc Process for producing 2,2'-o-cyclonucleosides, nucleosides and their analogous compounds
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
DE19518216A1 (de) * 1994-10-07 1996-04-11 Max Delbrueck Centrum Neue ß-L-Nucleoside und ihre Verwendung
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
KR100719606B1 (ko) * 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
TR200601784T2 (tr) * 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005026186A1 *

Also Published As

Publication number Publication date
US20060217345A1 (en) 2006-09-28
WO2005026186A1 (fr) 2005-03-24

Similar Documents

Publication Publication Date Title
DE69318031T2 (de) Ematiomerenreine beta-d-dioxolane nucleoside mit selektiver antihepatitis b-virus wirkung
DE69533066T2 (de) Verbindungen und verfahren zur behandlung von krebs
DE60208794T2 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
DE69929060T2 (de) Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
DE69206876T3 (de) Nukleosidanalogen enthaltende Antiviren-Zubereitungen
AT390000B (de) Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten
DE69933860T2 (de) 2'-fluoronukleoside
DE69425574T2 (de) L-2',3'-dideoxy-nukleosidanaloga als anti-hepatitis b-(hbv) und anti-hiv-wirkstoffe
EP0254268B2 (fr) Nucléosides fluorées, leur préparation et leur utilisation pharmaceutique contre le SIDA
DE69530192T2 (de) L-nukleoside zur behandlung des hepatitis-b- und epstein-bar-virus
DE3852531T2 (de) Nukleoside und nukleosid-analoge, pharmazeutische zusammensetzung und verfahren für die herstellung der bestandteile.
DE69636734T2 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
DE69720811T2 (de) L-Ribavirin und dessen Verwendung
WO1993016091A1 (fr) Nouveaux liponucleotides, leur fabrication ainsi que leur utilisation en tant que medicaments antiviraux
EP2137203B1 (fr) Analogues d'hétérodinucléoside phosphate ethynylatés, procédé de production et utilisation de ces derniers
WO1993016092A1 (fr) Nouveaux conjugues acide lipophosphonique-nucleosides et leur utilisation en tant que medicaments antiviraux
DD296687A5 (de) Nucleosid-derivate und deren verwendung als arzneimittel
WO2009042767A1 (fr) Analogues d'azacytidine et leurs utilisations
DE3855470T2 (de) Aristeromycin/Adenosin-Derivate
US20140031309A1 (en) Beta-L-N4 Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases
JPH02180894A (ja) 抗ウイルス剤
JP5461989B2 (ja) ヌクレオシド類、これらを含有する薬物とその使用
EP1668023A1 (fr) Nucleosides b-l et leur utilisation comme agents pharmaceutiques pour traiter des affections virales
WO1996025421A1 (fr) Conjugues lipidiques specifiques de diphosphates nucleosidiques et leur utilisation comme medicaments
WO2009129798A2 (fr) Promédicaments à base de diphosphate et de triphosphate, notamment promédicaments à base de nucléoside diphosphate et de nucléoside triphosphate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060411

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WILL, HANS

Inventor name: LI, LIN

Inventor name: MATTHES, ECKART

Inventor name: SIRMA, HUESEYIN

Inventor name: VON JANTA-LIPINSKI, MARTIN

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081113